Quick Answer
10x Genomics, Inc. reported Operating Income Loss of -$60.99 million for the year ending 2025.
- 10x Genomics, Inc. showed an increase of +68.7% in Operating Income Loss from 2024 to 2025.
- This data is from 10x Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$14.93 million | Q1 2019: -$3.04 million | Q2 2019: -$10.36 million | Q3 2019: -$9.10 million | Q1 2020: -$19.88 million | Q2 2020: -$39.42 million | Q3 2020: -$65.26 million | Q1 2021: -$10.22 million | Q2 2021: -$10.33 million | Q3 2021: -$15.88 million | Q1 2022: -$41.74 million | Q2 2022: -$63.12 million | Q3 2022: -$40.00 million | Q1 2023: -$51.99 million | Q2 2023: -$63.36 million | Q3 2023: -$94.80 million | Q1 2024: -$61.50 million | Q2 2024: -$41.74 million | Q3 2024: -$41.49 million | Q1 2025: -$39.33 million | Q2 2025: $30.13 million | Q3 2025: -$32.24 million.
- Over the full 9 years of available data (2017 to 2025), 10x Genomics, Inc.'s Operating Income Loss has declined by 231.9%.
- Historical annual values: Fiscal year 2025: -$60.99 million | Fiscal year 2024: -$194.56 million | Fiscal year 2023: -$265.33 million | Fiscal year 2022: -$167.94 million | Fiscal year 2021: -$52.25 million | Fiscal year 2020: -$534.14 million | Fiscal year 2019: -$30.57 million | Fiscal year 2018: -$110.76 million | Fiscal year 2017: -$18.38 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: